JP2021531311A5 - - Google Patents

Info

Publication number
JP2021531311A5
JP2021531311A5 JP2021504235A JP2021504235A JP2021531311A5 JP 2021531311 A5 JP2021531311 A5 JP 2021531311A5 JP 2021504235 A JP2021504235 A JP 2021504235A JP 2021504235 A JP2021504235 A JP 2021504235A JP 2021531311 A5 JP2021531311 A5 JP 2021531311A5
Authority
JP
Japan
Prior art keywords
membered
alkyl
cycloalkyl
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021504235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531311A (ja
JP7386842B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043112 external-priority patent/WO2020023551A1/en
Publication of JP2021531311A publication Critical patent/JP2021531311A/ja
Publication of JP2021531311A5 publication Critical patent/JP2021531311A5/ja
Application granted granted Critical
Publication of JP7386842B2 publication Critical patent/JP7386842B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021504235A 2018-07-24 2019-07-23 ナフチリジン化合物およびその使用 Active JP7386842B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018096781 2018-07-24
CNPCT/CN2018/096781 2018-07-24
PCT/US2019/043112 WO2020023551A1 (en) 2018-07-24 2019-07-23 Naphthyridine compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2021531311A JP2021531311A (ja) 2021-11-18
JP2021531311A5 true JP2021531311A5 (enExample) 2022-07-22
JP7386842B2 JP7386842B2 (ja) 2023-11-27

Family

ID=67551416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021504235A Active JP7386842B2 (ja) 2018-07-24 2019-07-23 ナフチリジン化合物およびその使用

Country Status (6)

Country Link
US (1) US12297210B2 (enExample)
EP (1) EP3826721B1 (enExample)
JP (1) JP7386842B2 (enExample)
CN (1) CN112533677A (enExample)
TW (1) TW202012405A (enExample)
WO (1) WO2020023551A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454070A (zh) * 2018-09-30 2021-09-28 豪夫迈·罗氏有限公司 噌啉化合物及用于hpk1依赖性疾患诸如癌症的治疗
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
TW202140473A (zh) 2020-01-15 2021-11-01 美商纜圖藥品公司 Map4k1抑制劑
WO2022063140A1 (en) * 2020-09-23 2022-03-31 Shenzhen Ionova Life Science Co., Ltd. Pyrimidine and pyridine derivatives as hpk1 modulator and methods using same
CN114907375B (zh) * 2021-02-07 2026-03-31 苏州信诺维医药科技股份有限公司 杂环化合物、其制备方法、药物组合物及应用
CN114907374B (zh) * 2021-02-07 2026-03-10 苏州信诺维医药科技股份有限公司 杂环化合物、其制备方法、药物组合物及应用
MX2024000751A (es) 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.
CN117940406A (zh) * 2021-07-15 2024-04-26 缆图药品公司 Map4k1抑制剂
EP4373817B1 (en) 2021-07-20 2025-05-21 Astrazeneca AB Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
KR20100044251A (ko) 2007-08-15 2010-04-29 싸이토키네틱스, 인코포레이티드 특정 화학 물질, 조성물 및 방법
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
NO2504364T3 (enExample) 2009-11-24 2018-01-06
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
EP2770998B1 (en) 2011-10-27 2020-04-29 Merck Sharp & Dohme Corp. Factor ixa inhibitors
ES2872555T3 (es) * 2015-06-25 2021-11-02 Univ Health Network Inhibidores de HPK1 y métodos de uso de los mismos
US20180072718A1 (en) * 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
JP7025426B2 (ja) * 2016-11-30 2022-02-24 アリアド ファーマシューティカルズ, インコーポレイテッド 造血前駆体キナーゼ1(hpk1)阻害剤としてのアニリノピリミジンas
BR112019018093A2 (pt) * 2017-03-30 2020-06-16 F. Hoffmann-La Roche Ag Compostos, composição, método de inibição de hpk1, métodos para melhorar uma resposta imune e para tratar um distúrbio e usos do composto

Similar Documents

Publication Publication Date Title
JP2021532109A5 (enExample)
RU2010111551A (ru) Замещенные индольные производные и способы их применения
JP2020512974A5 (enExample)
JP2021515010A5 (enExample)
JP2013532652A5 (enExample)
JP2021523099A5 (enExample)
RU2010111550A (ru) 2,3-замещенные индольные производные для лечения вирусных инфекций
RU2016102036A (ru) Производное хинолина
RU2013126041A (ru) Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2
JP2018528942A5 (enExample)
JP2021513534A5 (enExample)
JP2012526728A5 (enExample)
JP2019510798A5 (enExample)
JP2021534108A5 (enExample)
JP2017137291A5 (enExample)
AR076486A1 (es) Inhibidores de fosfoinositida 3 kinasa y composiciones farmaceuticas que los contienen.
JP2009543802A5 (enExample)
JP2019500387A5 (enExample)
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
JP2020500866A5 (enExample)
JP2012505871A5 (enExample)
JP2013512903A5 (enExample)
JP2015536947A5 (enExample)
RU2013108348A (ru) Конденсированные гетероарилы и их применение
RU2019116590A (ru) Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич